Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | SMYD3 | Q9H7B4 | 3/20 | 0.51 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.48 |
| ▸ | NAAA | Q02083 | 2/20 | 0.43 |
| ▸ | ACHE | P22303 | 6/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL84042 | 1.00 | GAA (0.52) | GAAMAPK1HTTSMN1; SMN2SMYD3 | |
| SCHEMBL23901023 | 0.94 | GAA (0.60) | GAAMAPK1HTTSMN1; SMN2SMYD3 | |
| SCHEMBL4719490 | 0.92 | GAA (0.59) | GAAMAPK1HTTSMN1; SMN2EPHX1 | |
| SCHEMBL13387564 | 0.92 | GAA (0.59) | GAAMAPK1HTTSMN1; SMN2EPHX1 | |
| SCHEMBL30827617 | 0.91 | GAA (0.50) | GAAMAPK1HTTSMN1; SMN2SMYD3 | |
| SCHEMBL16526220 | 0.86 | GAA (0.66) | GAAMAPK1HTTSMN1; SMN2EPHX1 | |
| SCHEMBL23199587 | 0.85 | GAA (0.50) | GAAMAPK1HTTSMN1; SMN2EPHX1 | |
| SCHEMBL8260235 | 0.85 | GAA (0.54) | GAAMAPK1HTTSMN1; SMN2EPHX1 | |
| SCHEMBL8259162 | 0.85 | GAA (0.54) | GAAMAPK1HTTSMN1; SMN2EPHX1 | |
| SCHEMBL2575225 | 0.85 | GAA (0.54) | GAAMAPK1HTTSMN1; SMN2EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024105007-A1 | AUTOPHAGY INDUCING COMPOUNDS AND USES THEREOF | Samsara Therapeutics Inc. (US) | 2024-05-23 | — | — | WO | disclosed |
| WO-2023212147-A1 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS | CELGENE CORPORATION (US) | 2023-11-02 | — | — | WO | disclosed |
| EP-4003980-A1 | HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 | Ribon Therapeutics Inc. (US) | 2022-06-01 | — | — | EP | disclosed |
| CN-113121562-A | Polycyclic compounds as inhibitors of bruton's tyrosine kinase | 詹森药业有限公司 | 2021-07-16 | — | — | CN | disclosed |
| CN-105246883-A | Dna-pk inhibitors | VERTEX PHARMA | 2016-01-13 | — | — | CN | disclosed |
| US-8129425-B2 | Contacting cell with hedgehog antagonist; moderator of cell proliferative, cell differentiation | CURIS, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-20060287385-A1 | Small organic molecule regulators of cell proliferation | CURIS, INC. | 2006-12-21 | — | — | US | disclosed |
| CN-1860113-A | Nicotinamide derivatives useful as PDE4 inhibitors | PFIZER (US) | 2006-11-08 | — | — | CN | disclosed |
| US-7115653-B2 | Small organic molecule regulators of cell proliferation | CURIS, INC. (US) | 2006-10-03 | — | — | US | disclosed |
| EP-1436287-A4 | SMALL ORGANIC MOLECULE REGULATORS OF CELL PROLIFERATION | CURIS INC (US) | 2005-10-26 | — | — | EP | disclosed |
| US-20050070578-A1 | Small organic molecule regulators of cell proliferation | CURIS, INC. | 2005-03-31 | — | — | US | disclosed |
| EP-1436287-A2 | SMALL ORGANIC MOLECULE REGULATORS OF CELL PROLIFERATION | Curis, Inc. (US) | 2004-07-14 | — | — | EP | disclosed |
| WO-2003027234-A9 | SMALL ORGANIC MOLECULE REGULATORS OF CELL PROLIFERATION | CURIS INC (US) | 2004-02-19 | — | — | WO | disclosed |
| US-20030139457-A1 | Small organic molecule regulators of cell proliferation | CURIS, INC. | 2003-07-24 | — | — | US | disclosed |
| WO-2003027234-A2 | SMALL ORGANIC MOLECULE REGULATORS OF CELL PROLIFERATION | CURIS, INC. (US) | 2003-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287385-A1 | Small organic molecule regulators of cell proliferation | GLI1, SHH, SMO | GAA 3845/4885MAPK1 870/4885HTT 2289/4885 |
| US-20030139457-A1 | Small organic molecule regulators of cell proliferation | GLI1, SHH, SMO | GAA 3845/4885MAPK1 870/4885HTT 2289/4885 |
| US-20050070578-A1 | Small organic molecule regulators of cell proliferation | GLI1, SHH, SMO | GAA 3845/4885MAPK1 870/4885HTT 2289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.